Condition
Chondrosarcomas
Total Trials
5
Recruiting
1
Active
1
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
25%
1 of 4 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 2 (2)
Trial Status
Completed4
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT02389244Phase 2Completed
A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas
NCT07315542RecruitingPrimary
Diagnostic and Therapeutic Targets in Cartilaginous Tumours
NCT01449149Not ApplicableCompleted
Proton Radiation for Chordomas and Chondrosarcomas
NCT00401388Phase 2CompletedPrimary
A Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas
NCT00797602Completed
Proton Therapy for Chordomas and/or Chondrosarcomas
Showing all 5 trials